Thomas John Charles bought KRYS
June 25, 2026 · Form 4 insider transaction
Thomas John Charles bought 1,000 shares of Krystal Biotech, Inc. at $179.25 per share, a transaction worth $179.3K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
1,000
Price
$179.25
Total value
$179.3K
InsiderThomas John Charles
Role—
CompanyKrystal Biotech, Inc. (KRYS)
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateJune 25, 2026
Filing dateJune 26, 2026
Shares owned after1,000
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.